- COMPOUNDS AND METHODS for the inhibition of HDAC
-
Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.
- -
-
Paragraph 0151-0152
(2015/11/24)
-
- Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: Reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect
-
A series of novel imidazoline derivatives was synthesized and evaluated as neuropeptide Y (NPY) Y5 receptor antagonists. Optimization of previously reported imidazoline leads, 1a and 1b, was attempted by introduction of substituents at the 5-position on the imidazoline ring and modification of the bis(4-fluorphenyl) moiety. A number of potent derivatives without human ether-a-go-go related gene potassium channel (hERG) activity were identified. Selected compounds, including 2a, were shown to have excellent brain and CSF permeability. Compound 2a displayed a suitable pharmacokinetic profile for chronic in vivo studies and potently inhibited D-Trp34NPY-induced acute food intake in rats. Oral administration of 2a resulted in a potent reduction of body weight in a diet-induced obese mouse model.
- Sato, Nagaaki,Ando, Makoto,Ishikawa, Shiho,Jitsuoka, Makoto,Nagai, Keita,Takahashi, Hirobumi,Sakuraba, Aya,Tsuge, Hiroyasu,Kitazawa, Hidefumi,Iwaasa, Hisashi,Mashiko, Satoshi,Gomori, Akira,Moriya, Ryuichi,Fujino, Naoko,Ohe, Tomoyuki,Ishihara, Akane,Kanatani, Akio,Fukami, Takehiro
-
supporting information; experimental part
p. 3385 - 3396
(2010/03/24)
-
- 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS
-
The invention relates to novel pyrimidine derivatives of Formula (I), which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.
- -
-
Page/Page column 57
(2008/06/13)
-
- Mandelic acid derivatives and their use as throbin inhibitors
-
There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
- -
-
Page/Page column 41
(2008/06/13)
-